{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:38:47Z","timestamp":1770993527813,"version":"3.50.1"},"reference-count":65,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.2217\/fon.14.81","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T13:02:57Z","timestamp":1417698177000},"page":"2201-2212","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Therapies Under Development"],"prefix":"10.1080","volume":"10","author":[{"given":"Sameer A","family":"Parikh","sequence":"first","affiliation":[{"name":"Mayo Clinic, Division of Hematology, Department of Medicine, 200 First Street SW, Rochester, MN55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R","family":"Litzow","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Division of Hematology, Department of Medicine, 200 First Street SW, Rochester, MN55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0325"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21932"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27617"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.294"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000009"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"issue":"21","key":"e_1_3_2_12_1","first-page":"170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer D","year":"2010","unstructured":"Hoelzer D , HuettmannA, KaulFet al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003. ASH Annu. Meet. Abstracts116(21), 170 (2010).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"issue":"21","key":"e_1_3_2_16_1","first-page":"2603","article-title":"Southwest Oncology Group Study S0910: a Phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukemia","volume":"120","author":"Advani A","year":"2012","unstructured":"Advani A , McdonoughS, CoutreSet al. Southwest Oncology Group Study S0910: a Phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukemia. ASH Annu. Meet. Abstracts120(21), 2603 (2012).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"issue":"21","key":"e_1_3_2_18_1","first-page":"2612","article-title":"Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia","volume":"120","author":"Deangelo D","year":"2012","unstructured":"Deangelo D , StockW, PetersdorfSet al. Weekly inotuzumab ozogamicin in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia. ASH Annu. Meet. Abstracts120(21), 2612 (2012).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.261"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164129"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.27.9836"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.2664.2664"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.6.6"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0580"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181bdf211"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08387.x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"issue":"21","key":"e_1_3_2_30_1","first-page":"671","article-title":"Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL)","volume":"120","author":"O'Brien S","year":"2012","unstructured":"O'Brien S , ThomasDA, JorgensenJLet al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL). ASH Annu. Meet. Abstracts120(21), 671 (2012).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2980"},{"issue":"21","key":"e_1_3_2_32_1","first-page":"248","article-title":"A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia (ALL)","volume":"118","author":"Wayne AS","year":"2011","unstructured":"Wayne AS , BhojwaniD, SilvermanLBet al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia (ALL). ASH Annu. Meet. Abstracts118(21), 248 (2011).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"issue":"22","key":"e_1_3_2_35_1","first-page":"838","article-title":"Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final Phase I results of a Cancer and Leukemia Group B Study (CALGB 10.02)","volume":"114","author":"Stock W","year":"2009","unstructured":"Stock W , SanfordB, LozanskiGet al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final Phase I results of a Cancer and Leukemia Group B Study (CALGB 10.02). ASH Annu. Meet. Abstracts114(22), 838 (2009).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403422"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21901"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.69.69"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-060512-150254"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2309"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701344899"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017012"},{"issue":"21","key":"e_1_3_2_47_1","first-page":"867","article-title":"Final report of a Phase I trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia (ALL)","volume":"116","author":"Garcia-Manero G","year":"2010","unstructured":"Garcia-Manero G , ThomasDA, RyttingMEet al. Final report of a Phase I trial of decitabine with or without hyperCVAD in relapsed acute lymphocytic leukemia (ALL). ASH Annu. Meet. Abstracts116(21), 867 (2010).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80752-7"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.030"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-418640"},{"issue":"21","key":"e_1_3_2_51_1","first-page":"2192","article-title":"Phase II study of bortezomib, mitoxantrone and etoposide in relapsed\/refractory acute leukemias","volume":"116","author":"Filicko-O'hara J","year":"2010","unstructured":"Filicko-O'hara J , MookerjeeB, AlpdoganOet al. Phase II study of bortezomib, mitoxantrone and etoposide in relapsed\/refractory acute leukemias. ASH Annu. Meet. Abstracts116(21), 2192 (2010).","journal-title":"ASH Annu. Meet. Abstracts"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70339-5"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808253"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.232.232"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-329441"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.010"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23550"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23502"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4728"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.312"},{"key":"e_1_3_2_62_1","first-page":"163","article-title":"Recent advances on NOTCH signaling in T-ALL","volume":"360","author":"Tzoneva G","year":"2012","unstructured":"Tzoneva G , FerrandoAA. Recent advances on NOTCH signaling in T-ALL. Curr. Top Microbiol. Immunol.360, 163\u2013182 (2012).","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1102160"},{"key":"e_1_3_2_64_1","article-title":"A Phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias","volume":"24","author":"Deangelo Dj SR","year":"2006","unstructured":"Deangelo Dj SR , SilvermanLbet al. A Phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia\/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol.24(Suppl), Abstract 6585 (2006).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5292"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.828.828"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.14.81","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:17Z","timestamp":1719125057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.14.81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":65,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.2217\/fon.14.81"],"URL":"https:\/\/doi.org\/10.2217\/fon.14.81","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-12-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}